Sun Pharmaceutical’s U.S.-based Taro Pharmaceutical Industries helped the Indian drugmaker boost its U.S. sales in its last fiscal year, but the skin care specialist has hit a small manufacturing ...

New Delhi, Jun 22: Drug firm Lupin today said it has launched generic Desoximetasone cream used for the treatment of inflammation and itching of skin, in the US market. The company has launched its ...

Lupin launched Desoximetasone Cream USP, 0.05 percent and Desoximetasone Cream USP, 0.25 percent having received an approval from the USFDA earlier. It has come to our attention that certain ...

Lupin has received final approval for its Desoximetasone cream USP, 0.05 percent and Desoximetasone cream USP, 0.25 percent from the USFDA to market a generic equivalent of Taro Pharmaceuticals North ...

Perrigo Company plc PRGO recently announced that the FDA has approved its first-to-file AB rated generic version of Taro Pharmaceuticals USA Inc.'s TARO Topicort spray, 0.25% (desoximetasone topical ...

Lupin said in a BSE filing that it "has received final approval for its Desoximetasone cream USP, 0.05 per cent and Desoximetasone cream USP, 0.25 per cent from the United States Food and Drug ...

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (NYS: TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New ...

HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (TARO) ("Taro") reported today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its New Drug ...

Jan 11 (Reuters) - Lupin Ltd : * Lupin receives FDA approval for generic Topicort LP Emollient cream, 0.05% and Topicort cream, 0.25% Sign up here. * Products are indicated for the relief of the ...

Desoximetasone 0.25%. Avoid use on eyes, face, axilla, or groin. Do not use on pre-existing skin atrophy. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large ...

European satellite operator SES on Monday reported full-year results in line with market expectations and lowered its 2026 capital spending target, as it prepares to launch up to 13 satellites later ...